Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Which treatment is best for patients with stable ischemic heart disease?

Which treatment is best for patients with stable ischemic heart disease?

Posted by on May 6, 2021 in Coronary artery disease | 0 comments

In a nutshell This study compared the treatment of stable ischemic heart disease (SIHD) with percutaneous coronary angioplasty (PCI) or with medication alone. It found that the risk of mortality was the same in both groups. Some background Coronary artery disease (CAD) is when the blood vessels in the heart become blocked and the heart muscle...

Read More

Can ertugliflozin improve diabetes and blood pressure in patients who have heart disease?

Can ertugliflozin improve diabetes and blood pressure in patients who have heart disease?

Posted by on May 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the ertugliflozin (Steglatro) for patients with type 2 diabetes (T2D) and heart disease. It found that ertugliflozin improved both blood glucose control, body weight, and blood pressure. Some background T2D is a condition in which the levels of glucose (sugar) in the blood are too high. T2D is related to...

Read More

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?

Posted by on May 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated...

Read More

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Posted by on May 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...

Read More

Can nivolumab plus ipilimumab combined with chemotherapy be used as a first-line treatment for patients with non-small cell lung cancer?

Can nivolumab plus ipilimumab combined with chemotherapy be used as a first-line treatment for patients with non-small cell lung cancer?

Posted by on May 6, 2021 in Lung cancer | 0 comments

In a nutshell This trial looked at nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of chemotherapy as treatment for patients with non-small cell lung cancer (NSCLC). The authors found that this combination provided an improved overall survival versus chemotherapy-only regimens. Some background NSCLC is responsible for 85% of...

Read More

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Evaluating pirtobrutinib for the treatment on B cell leukemia/lymphoma

Posted by on Apr 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...

Read More

Does low dose colchicine reduce the risk of heart attack or stroke in high risk patients?

Does low dose colchicine reduce the risk of heart attack or stroke in high risk patients?

Posted by on Apr 30, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at the use of colchicine (Colcrys) in the treatment of coronary artery disease (CAD). It found that patients treated with colchicine had a lower risk of heart attack, stroke, or heart disease-related death. Some background CAD is a disease in which the blood vessels in the heart become blocked. It can...

Read More

Which type of insulin is best for avoiding hypoglycemia in patients with high risk type 2 diabetes?

Which type of insulin is best for avoiding hypoglycemia in patients with high risk type 2 diabetes?

Posted by on Apr 30, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the risk of hypoglycemia (dangerously low blood glucose levels) for insulin glargine 300 U/ml (Gla-300; Toujeo) and standard-of-care basal insulin (SOC-BI) at patients with type 2 diabetes (T2D) with risk factors for hypoglycemia. It found that Gla-300 was associated with a lower risk of hypoglycemia than...

Read More

Should durvalumab be considered a first-line treatment for extensive small cell lung cancer?

Should durvalumab be considered a first-line treatment for extensive small cell lung cancer?

Posted by on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness of durvalumab (Imfinzi) with or without tremelimumab plus platinum-etoposide (Etopophos) (PE) versus PE-alone for the treatment of extensive-stage small-cell lung cancer (ESCLC). The authors found that durvalumab plus PE showed sustain survival improvement in these patients. Some background...

Read More